Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Next Previous
Trial Profile

Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PALOMINO
  • Sponsors Apellis Pharmaceuticals

Most Recent Events

  • 19 Aug 2022 Results of pooled analysis assessing safety and efficacy of pegcetacoplan in complement inhibitor-naive adults (≥ 18 years) diagnosed with PNH published in the Annals of Hematology
  • 14 Dec 2021 Results of post hoc analysis from PEGASUS, PADDOCK and PALOMINO trials presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 08 Dec 2020 Results from Paddock and Palomino studies assessing the safety and preliminary efficacy of pegcetacoplan in complement inhibitor naive patients, presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top